BC
CALA

Birchview Capital’s Calithera Biosciences, Inc CALA Stock Holding History

Birchview Capital’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-985
Closed -$141K – 44
2015
Q2 		$141K Buy
+985
New +$228K 0.07% 41

Other funds holding CALA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Birchview Capital's CALA Position: Q3 2015 in Review

Birchview Capital sold out of Calithera Biosciences, Inc (CALA) in Q3 2015, closing a stake of 985 shares — an estimated $141K sold.

Birchview Capital first reported a position in CALA in Q2 2015 and held it in 1 quarter. The position peaked at $141K in Q2 2015. 49 funds tracked by Wall St. Rank hold CALA as of Q3 2015.

  • Birchview Capital reported no remaining Calithera Biosciences, Inc position as of Q3 2015 after selling out during the quarter.
  • Birchview Capital sold 985 Calithera Biosciences, Inc shares in Q3 2015, an estimated $141K.
  • Birchview Capital first reported a position in Calithera Biosciences, Inc in Q2 2015 and held it in 1 quarter.
  • Birchview Capital's Calithera Biosciences, Inc position peaked at $141K in Q2 2015.
  • 49 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q3 2015.

Based on Birchview Capital's 13F filing for Q3 2015, filed 6 Nov 2015.